RTP-based SCYNEXIS (www.scynexis.com), a drug discovery and development company, has received a milestone payment as part of its multi-year research collaboration with U.K.-based Merial which began in 2005. SCYNEXIS focuses on medicinal chemistry, advanced biological screening, and bioanalytical efforts towards Merial’s animal health discovery efforts. Details of the payment were not disclosed.
SCYNEXIS is a CED member.